封面
市场调查报告书
商品编码
1825298

放射治疗市场:2025-2030 年预测

Radiotherapy Market - Forecasts from 2025 to 2030

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

放射治疗市场预计将从 2025 年的 70.38 亿美元成长到 2030 年的 89.97 亿美元,复合年增长率为 5.03%。

放射治疗市场是全球癌症治疗的重要组成部分,透过标靶放射治疗消灭癌细胞,同时保护健康组织。全球超过50%的癌症病例采用放射治疗,是癌症治疗的基石,通常与手术和化疗合併使用。癌症发生率上升、技术进步以及医疗保健投资的增加推动了放射治疗市场的发展,尤其是在亚太地区、北美和欧洲。儘管存在高成本和专家短缺等挑战,但预计到2030年,在精准放射治疗创新和肿瘤学基础设施不断扩展的推动下,放射治疗市场仍将实现强劲增长。

市场概况

放射治疗使用电离辐射瞄准恶性细胞,为前列腺癌、乳癌、肺癌和头颈部癌等癌症提供非侵入性或微创治疗。体外放射治疗(EBRT) 使用直线加速器 (线性加速器) 来瞄准前列腺癌和子宫颈癌等局部癌症。全身性治疗使用放射性药物治疗甲状腺癌等癌症。最终用户主要是管理复杂病例的医院,而门诊手术中心则治疗门诊病人。到 2025 年,市场将反映出全球癌症负担的增加,2020 年报告的新诊断病例为 1,930 万,预计到 2030 年将显着增加(世界卫生组织,2020 年)。治疗计划中的人工智慧和机器学习等创新正在透过提高精确度来推动市场扩张,特别是在 EBRT 和近距离放射治疗方面。

驱动程式

推动放射治疗市场的关键因素是:

  • 癌症发生率上升:随着全球癌症病例数预计增加,放射治疗的需求也显着增加。
  • 技术进步:影像导航放射治疗(IGRT) 和立体定位放射治疗 (SBRT) 等创新技术正在改善治疗效果。 2024 年 3 月,瓦里安推出了 Halcyon 3.0 系统,该系统提高了影像引导的精确度(西门子医疗,2024 年)。 2024 年 4 月,医科达推出了用于治疗摄护腺癌的 Harmony Pro(医科达公司,2024 年)。
  • 医疗保健投资:各国政府正在扩大癌症治疗基础设施:印度将在 2024 年为癌症治疗拨款 12 亿美元(厚生劳动省,2024 年),日本已在质子治疗中心投资 10 亿美元(日本厚生劳动省,2024 年)。
  • 老化:到 2024 年,全球 10% 的人口将年龄在 65 岁或以上,这将导致癌症发病率上升和放射治疗需求增加(联合国,2024 年)。

市场限制

挑战如下:

  • 高成本:质子治疗机等先进系统价格昂贵,限制了其在资源贫乏地区的普及。
  • 副作用:疲劳和皮肤损伤等与放射线相关的问题可能会阻碍一些患者的治疗。
  • 专家短缺:全球范围内训练有素的肿瘤学家和技术人员的短缺影响了服务的提供。

区域分析

  • 北美:2024年美国将新增190万例癌症病例,先进的医疗基础设施将推动市场发展(美国癌症协会,2024年)。 EBRT将占治疗的80%,其中医院占主导地位。美国医疗支出将达4.5兆美元,FDA将在2024年核准15种新的放射治疗设备(美国食品药物管理局,2024年)。加拿大将在癌症治疗方面投资5亿美元,墨西哥的癌症治疗设施将增加10%(加拿大癌症协会,2024年;墨西哥卫生署,2024年)。
  • 亚太地区:成长最快的地区,主要得益于中国480万癌症患者以及印度2024年癌症负担成长8%(中国国家癌症中心,2024年;日本厚生劳动省,2024年)。住院治疗占90%,其中65%的病例采用外放射治疗(EBRT)。日本和韩国在质子治疗和人工智慧整合系统方面正在取得进展,其中日本将在2024年投资10亿美元(日本卫生署,2024年)。
  • 欧洲:德国和英国将引领癌症成长,其中德国报告2024年新增癌症病例50万例(德国癌症研究中心,2024年)。 85%的治疗在医院进行,主要是外放射治疗(EBRT)。法国将在肿瘤学领域投资15亿欧元,欧盟在2024年拨款40亿欧元用于癌症研究(法国卫生署,2024年;欧盟委员会,2024年)。

細項分析

  • 体外放射治疗 (EBRT):这是最大的细分市场,2024 年将用于全球 70% 的治疗,受益于 Varian 的 Halcyon 3.0 和 Accuray 的 Cyber​​curKnife S7 等系统,后者于 2024 年 1 月进行了升级(Accuray Incorporated,2024 年)。
  • 摄护腺癌:这是一种关键的应用,到 2024 年将影响美国250,000 例前列腺癌病例,并将受益于 Elekta 的 Harmony Pro 增强型 EBRT 和近距离放射治疗(美国癌症协会,2024 年;Elekta AB,2024 年)。
  • 医院:最终用户,即医院,提供 80% 的治疗,并得到先进基础设施和投资的支持,例如英国5 亿英镑的癌症基金(英国卫生署,2024 年)。

由于癌症发病率上升、技术进步和医疗保健投资增加,放射治疗市场蓬勃发展。北美地区处于领先地位,亚太地区也正经历快速成长。行业专家应关注技术创新、法规合规性和区域趋势,以抓住2030年前的机会。

本报告的主要优点

  • 深刻分析:获得深入的市场洞察,重点关注客户细分、政府政策和社会经济因素、消费者偏好、垂直行业和其他细分市场,涵盖主要地区和新兴地区。
  • 竞争格局:了解主要企业所采用的策略策略,并了解正确策略的市场渗透潜力。
  • 市场趋势和驱动因素:探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议:利用洞察力进行策略决策,并在动态环境中开闢新的业务流和收益。
  • 适合广泛的使用者:对于新兴企业、研究机构、顾问、中小企业和大型企业来说都是有益且具有成本效益的。

它有什么用途?

产业与市场考量、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

调查范围

  • 2022 年至 2024 年的历史数据和 2025 年至 2030 年的预测数据
  • 成长机会、挑战、供应链前景、法律规范与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 收益成长和预测细分市场和区域分析(包括国家)
  • 公司概况(尤其是财务状况和关键发展)

目录

第一章执行摘要

第二章市场概述

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 经营状况

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策法规
  • 策略建议

第四章 技术展望

第五章放射治疗市场:依产品

  • 介绍
  • 硬体
  • 软体和服务

第六章放射治疗市场(按类型)

  • 介绍
  • 体内放射疗法
  • 体外放射线治疗
    • 3D适形放射治疗(3D-CRT)
    • 强度调控放射治疗(IMRT)
    • 影像导航放射治疗(IGRT)
    • 其他的

第七章放射治疗市场:依应用

  • 介绍
  • 摄护腺癌
  • 乳癌
  • 肺癌
  • 头颈癌
  • 其他的

第八章放射治疗市场(按最终用户)

  • 介绍
  • 医院
  • 门诊手术中心
  • 其他的

第九章放射治疗市场(按地区)

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 台湾
    • 其他的

第十章竞争格局及分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第 11 章:公司简介

  • Elekta AB
  • Accuray Incorporated
  • Ion Beam Applications Group
  • Canon Medical Systems Corporation
  • Mirada Medical
  • Eckert & Ziegler
  • Siemens Healthineers
  • Mevion Medical Systems, Inc.
  • ALCEN(PMB)
  • CQ Medical

第十二章 附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061610003

The Radiotherapy Market is expected to grow from USD 7.038 billion in 2025 to USD 8.997 billion in 2030, at a CAGR of 5.03%.

The Radiotherapy Market is a critical component of global cancer care, delivering targeted radiation to eradicate cancerous cells while sparing healthy tissues. Utilized in over 50% of cancer cases worldwide, radiotherapy is a cornerstone treatment, often combined with surgery or chemotherapy. The market is driven by rising cancer prevalence, technological advancements, and increasing healthcare investments, particularly in Asia-Pacific, North America, and Europe. Despite challenges such as high costs and professional shortages, the market is poised for robust growth through 2030, fueled by innovations in precision radiotherapy and expanding oncology infrastructure.

Market Overview

Radiotherapy employs ionizing radiation to target malignant cells, offering non-invasive or minimally invasive treatment for cancers like prostate, breast, lung, and head and neck. External beam radiotherapy (EBRT) uses linear accelerators for versatile applications, while brachytherapy targets localized cancers like prostate and cervical. Systemic radiotherapy, using radioactive drugs, addresses cancers such as thyroid. Hospitals dominate as end-users, managing complex cases, while ambulatory surgical centers handle outpatient procedures. In 2025, the market reflects a growing global cancer burden, with 19.3 million new diagnoses reported in 2020 and projections for significant increases by 2030 (World Health Organization, 2020). Innovations like AI and machine learning in treatment planning enhance precision, particularly for EBRT and brachytherapy, supporting market expansion.

Growth Drivers

Key factors driving the Radiotherapy Market include:

  • Rising Cancer Prevalence: With a projected rise in global cancer cases, demand for radiotherapy is increasing significantly.
  • Technological Advancements: Innovations like image-guided radiotherapy (IGRT) and stereotactic body radiotherapy (SBRT) improve outcomes. In March 2024, Varian launched the Halcyon 3.0 system, enhancing image-guided precision (Siemens Healthineers, 2024). In April 2024, Elekta introduced the Harmony Pro for prostate cancer treatment (Elekta AB, 2024).
  • Healthcare Investments: Governments are expanding oncology infrastructure. India allocated $1.2 billion to cancer care in 2024 (Ministry of Health and Family Welfare, 2024), while Japan invested $1 billion in proton therapy centers (Japanese Ministry of Health, 2024).
  • Aging Population: In 2024, 10% of the global population was over 65, driving higher cancer incidence and radiotherapy demand (United Nations, 2024).

Market Restraints

Challenges include:

  • High Costs: Advanced systems like proton therapy units are expensive, limiting access in low-resource regions.
  • Side Effects: Radiation-related issues like fatigue and skin damage deter some patients.
  • Professional Shortages: A global lack of trained oncologists and technicians impacts service delivery.

Geographical Analysis

  • North America: The region leads the market, driven by advanced healthcare infrastructure and 1.9 million new cancer cases in the U.S. in 2024 (American Cancer Society, 2024). Hospitals dominate, with 80% of treatments using EBRT. The U.S. healthcare expenditure reached $4.5 trillion, and the FDA approved 15 new radiotherapy devices in 2024 (U.S. Food and Drug Administration, 2024). Canada invested $500 million in cancer care, while Mexico's oncology facilities grew by 10% (Canadian Cancer Society, 2024; Mexican Ministry of Health, 2024).
  • Asia-Pacific: The fastest-growing region, led by China's 4.8 million cancer cases and India's 8% cancer burden increase in 2024 (National Cancer Center of China, 2024; Ministry of Health and Family Welfare, 2024). Hospitals account for 90% of treatments, with EBRT used in 65% of cases. Japan and South Korea advance through proton therapy and AI-integrated systems, with Japan investing $1 billion in 2024 (Japanese Ministry of Health, 2024).
  • Europe: Germany and the UK drive growth, with Germany reporting 500,000 new cancer cases in 2024 (German Cancer Research Center, 2024). Hospitals deliver 85% of treatments, primarily EBRT. France invested €1.5 billion in oncology, and the EU allocated €4 billion for cancer research in 2024 (French Ministry of Health, 2024; European Commission, 2024).

Segment Analysis

  • External Beam Radiotherapy (EBRT): The largest segment, used in 70% of global treatments in 2024, benefits from systems like Varian's Halcyon 3.0 and Accuray's CyberKnife S7, upgraded in January 2024 (Accuray Incorporated, 2024). Its versatility and AI integration drive growth.
  • Prostate Cancer: A key application, with 250,000 U.S. cases in 2024, benefits from EBRT and brachytherapy, enhanced by Elekta's Harmony Pro (American Cancer Society, 2024; Elekta AB, 2024).
  • Hospitals: Dominating end-users, hospitals handle 80% of treatments, supported by advanced infrastructure and investments like the UK's £500 million cancer fund (UK Department of Health, 2024).

Key Developments

  • Varian Halcyon 3.0: Launched in March 2024, enhancing EBRT precision (Siemens Healthineers, 2024).
  • Elekta Harmony Pro: Introduced in April 2024, optimized for prostate cancer (Elekta AB, 2024).
  • Accuray CyberKnife S7 Upgrade: Improved SBRT delivery in January 2024 (Accuray Incorporated, 2024).
  • Regional Investments: India ($1.2 billion), Japan ($1 billion), EU (€4 billion), and U.S. (15 FDA approvals) in 2024 bolster market growth.

The Radiotherapy Market is thriving, driven by rising cancer rates, technological advancements, and healthcare investments. North America leads, with Asia-Pacific growing rapidly. Industry experts should focus on innovation, regulatory compliance, and regional trends to leverage opportunities through 2030.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Radiotherapy Market Segmentation:

By Offering

  • Hardware
  • Software & Services

By Type

  • Internal Radiation Therapy
  • External Radiation Therapy
  • 3D-Conformal Radiation Therapy (3D-CRT)
  • Intensity-Modulated Radiation Therapy (IMRT)
  • Image Guided Radiotherapy (IGRT)
  • Others

By Application

  • Prostate Cancer
  • Breast Cancer
  • Lung Cancer
  • Head & Neck Cancer
  • Others

By End-User

  • Hospital
  • Ambulatory Surgical Center
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. RADIOTHERAPY MARKET BY OFFERING

  • 5.1. Introduction
  • 5.2. Hardware
  • 5.3. Software & Services

6. RADIOTHERAPY MARKET BY TYPE

  • 6.1. Introduction
  • 6.2. Internal Radiation Therapy
  • 6.3. External Radiation Therapy
    • 6.3.1. 3D-Conformal Radiation Therapy (3D-CRT)
    • 6.3.2. Intensity-Modulated Radiation Therapy (IMRT)
    • 6.3.3. Image Guided Radiotherapy (IGRT)
    • 6.3.4. Others

7. RADIOTHERAPY MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Prostate Cancer
  • 7.3. Breast Cancer
  • 7.4. Lung Cancer
  • 7.5. Head & Neck Cancer
  • 7.6. Others

8. RADIOTHERAPY MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospital
  • 8.3. Ambulatory Surgical Center
  • 8.4. Others

9. RADIOTHERAPY MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. USA
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. Germany
    • 9.4.2. France
    • 9.4.3. United Kingdom
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Israel
    • 9.5.4. Others
  • 9.6. Asia Pacific
    • 9.6.1. China
    • 9.6.2. India
    • 9.6.3. Japan
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Taiwan
    • 9.6.8. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Elekta AB
  • 11.2. Accuray Incorporated
  • 11.3. Ion Beam Applications Group
  • 11.4. Canon Medical Systems Corporation
  • 11.5. Mirada Medical
  • 11.6. Eckert & Ziegler
  • 11.7. Siemens Healthineers
  • 11.8. Mevion Medical Systems, Inc.
  • 11.9. ALCEN (PMB)
  • 11.10. CQ Medical

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key benefits for the stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations